Download PDF
Dtsch Med Wochenschr 2021; 146(S 01): S2-S16
DOI: 10.1055/a-1472-3188
Konsensuspapier

Interdisziplinäre Aspekte der oralen Antikoagulation mit NOAKs bei Vorhofflimmern

Interdisciplinary aspects of oral anticoagulation with NOACs in atrial fibrillation
Daniel Dürschmied
1   Kardiologie, Universitäts-Herzzentrum Freiburg
,
Andreas Goette
2   Medizinische Klinik II: Kardiologie und Intensivmedizin, St. Vincenz-Krankenhaus Paderborn GmbH
,
Roland Hardt
3   Abteilung Geriatrie, Universitätsklinik Mainz
,
Christoph Kleinschnitz
4   Neurologie, Universitätsklinik Essen
,
Wolfgang Kämmerer
5   Apotheke, Universitätsklinik Augsburg
,
Christoph Lembens
6   Praxis für Innere Medizin und Allgemeinmedizin, Mainz
,
Wilhelm Schmitt
7   Nierenzentrum Weinheim
,
Christoph Bode
1   Kardiologie, Universitäts-Herzzentrum Freiburg
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Corrected by:

Interdisziplinäre Aspekte der oralen Antikoagulation mit NOAKs bei VorhofflimmernDtsch Med Wochenschr 2021; 146(S 01): S1-S1
DOI: 10.1055/a-1902-3580

Zusammenfassung

Die Schlaganfallprophylaxe mit nicht von Vitamin K abhängigen oralen Antikoagulanzien (NOAKs) bei Patienten mit nichtvalvulärem Vorhofflimmern (nvVHF) hat heute einen festen Platz in der klinischen Routine. Die Definition des nvVHF umfasst die Abwesenheit einer mechanischen Herzklappe und ein nicht mit einer mittel- oder hochgradigen Mitralklappenstenose einhergehendes Vorhofflimmern. Das Management der oralen Antikoagulation (OAK) erfordert eine starke Interdisziplinarität. Nicht zuletzt aus diesem Grund sind in der Praxis immer wieder Unsicherheiten zu beobachten, die für den einzelnen Patienten weitreichende Folgen haben können. Deshalb hat sich ein Gremium aus Vertretern von Allgemeinmedizin, Geriatrie, Kardiologie, Nephrologie und Neurologie versammelt, um praxisrelevante Aspekte aus den verschiedenen Disziplinen zu identifizieren und gemeinsam praktische Handreichungen zu erarbeiten, die die Therapiesicherheit für die Patienten im Alltag verbessern sollen (Übersicht siehe [Abb. 1]).

Abstract

Stroke prophylaxis with non-vitamin K-dependent oral anticoagulants (NOAKs) in patients with non-valvular atrial fibrillation (nvVHF) is now firmly established in routine clinical practice. The definition of nvVHF includes the absence of a mechanical heart valve and AF not associated with moderate- or high-grade mitral valve stenosis. The management of oral anticoagulation (OAC) requires a high degree of interdisciplinarity. Not least for this reason, uncertainties are repeatedly observed in practice, which can have far-reaching consequences for the individual patient. For this reason, a committee consisting of representatives from general medicine, geriatrics, cardiology, nephrology and neurology has gathered to identify aspects of practical relevance from the various disciplines and to jointly develop practical guidelines to improve therapy safety for patients in everyday life.

Schlüsselwörter

Vorhofflimmern - Antikoagulation - NOAK

Key words

Atrial fibrillation - anticoagulation - NOAK


Publication History

Article published online:
06 May 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Referenzen

  • 1 Goette A. Antithrombotic therapy after coronary artery stenting in atrial fibrillation: dual therapy encompassing NOAC plus P2Y12 inhibitor is ready for prime time!. Annals of translational medicine 2019; 7: S270
    CrossrefPubMedSearch in Google Scholar
  • 2 Kaplan RM, Koehler J, Ziegler PD. et al Stroke Risk as a Function of Atrial Fibrillation Duration and CHA2DS2-VASc Score. Circulation 2019; 140: 1639-1646
    CrossrefPubMedSearch in Google Scholar
  • 3 Hindricks G, Potpara T, Dagres N. et al 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J 2020;
    CrossrefPubMedSearch in Google Scholar
  • 4 Fachinformation Eliquis®, Pfizer Pharma GmbH, Berlin. Stand Januar 2021
    PubMed
  • 5 Fachinformation Lixiana®, Daiichi Sankyo Europe GmbH, München, Deutschland. Stand Juni 2020
    PubMed
  • 6 Fachinformation Pradaxa®, Böhringer Ingelheim International GmbH, Ingelheim am Rhein. Stand Mai 2020. In
    PubMed
  • 7 Fachinformation Xarelto®, Bayer Pharma AG, Berlin. Stand Oktober 2019. In
    PubMed
  • 8 Connolly SJ, Ezekowitz MD, Yusuf S. et al Dabigatran versus warfarin in patients with atrial fibrillation. The New England journal of medicine 2009; 361: 1139-1151
    CrossrefPubMedSearch in Google Scholar
  • 9 Giugliano RP, Ruff CT, Braunwald E. et al Edoxaban versus warfarin in patients with atrial fibrillation. The New England journal of medicine 2013; 369: 2093-2104
    CrossrefPubMedSearch in Google Scholar
  • 10 Granger CB, Alexander JH, McMurray JJ. et al Apixaban versus warfarin in patients with atrial fibrillation. The New England journal of medicine 2011; 365: 981-992
    CrossrefPubMedSearch in Google Scholar
  • 11 Patel MR, Mahaffey KW, Garg J. et al Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. The New England journal of medicine 2011; 365: 883-891
    CrossrefPubMedSearch in Google Scholar
  • 12 Ruff CT, Giugliano RP, Braunwald E. et al Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955-962
    Search in Google Scholar
  • 13 Reinecke H, Brand E, Mesters R. et al Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol 2009; 20: 705-711
    CrossrefPubMedSearch in Google Scholar
  • 14 Garlo KG, Steele DJR, Nigwekar SU. et al Demystifying the Benefits and Harms of Anticoagulation for Atrial Fibrillation in Chronic Kidney Disease. Clin J Am Soc Nephrol 2019; 14: 125-136
    CrossrefPubMedSearch in Google Scholar
  • 15 Fachinformation Marcumar®, MEDA Pharma GmbH & Co. KG, Bad Homburg. Stand Juni 2018. In
    PubMed
  • 16 Schurgers LJ, Joosen IA, Laufer EM. et al Vitamin K-antagonists accelerate atherosclerotic calcification and induce a vulnerable plaque phenotype. PLoS One 2012; 7: e43229
    CrossrefPubMedSearch in Google Scholar
  • 17 Brandenburg VM, Kramann R, Rothe H. et al Calcific uraemic arteriolopathy (calciphylaxis): data from a large nationwide registry. Nephrol Dial Transplant 2017; 32: 126-132
    CrossrefPubMedSearch in Google Scholar
  • 18 Böhm M, Ezekowitz MD, Connolly SJ. et al Changes in Renal Function in Patients With Atrial Fibrillation: An Analysis From the RE-LY Trial. J Am Coll Cardiol 2015; 65: 2481-2493
    CrossrefPubMedSearch in Google Scholar
  • 19 Kimachi M, Furukawa TA, Kimachi K. et al Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease. Cochrane Database Syst Rev 2017; 11: CD011373
    CrossrefPubMedSearch in Google Scholar
  • 20 Feldberg J, Patel P, Farrell A. et al A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation. Nephrol Dial Transplant 2019; 34: 265-277
    CrossrefPubMedSearch in Google Scholar
  • 21 Bohula EA, Giugliano RP, Ruff CT. et al Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial. Circulation 2016; 134: 24-36
    CrossrefPubMedSearch in Google Scholar
  • 22 Hohnloser SH, Hijazi Z, Thomas L. et al Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012; 33: 2821-2830
    CrossrefPubMedSearch in Google Scholar
  • 23 Ha JT, Neuen BL, Cheng LP. et al Benefits and Harms of Oral Anticoagulant Therapy in Chronic Kidney Disease: A Systematic Review and Meta-analysis. Ann Intern Med 2019; 171: 181-189
    CrossrefPubMedSearch in Google Scholar
  • 24 Herzog CA, Asinger RW, Berger AK. et al Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2011; 80: 572-586
    CrossrefPubMedSearch in Google Scholar
  • 25 Kuno T, Takagi H, Ando T. et al Oral Anticoagulation for Patients With Atrial Fibrillation on Long-Term Hemodialysis. J Am Coll Cardiol 2020; 75: 273-285
    CrossrefPubMedSearch in Google Scholar
  • 26 Van Der Meersch H, De Bacquer D, De Vriese AS. Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: A systematic review and meta-analysis. Am Heart J 2017; 184: 37-46
    CrossrefPubMedSearch in Google Scholar
  • 27 Siontis KC, Zhang X, Eckard A. et al Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States. Circulation 2018; 138: 1519-1529
    CrossrefPubMedSearch in Google Scholar
  • 28 Chan KE, Edelman ER, Wenger JB. et al Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation 2015; 131: 972-979
    CrossrefPubMedSearch in Google Scholar
  • 29 Cascorbi I. Drug interactions – principles, examples and clinical consequences. Dtsch Arztebl Int 2012; 109 (33) 546-556
    CrossrefPubMedSearch in Google Scholar
  • 30 Moßhammer D, Haumann H, Mörike K. et al Polypharmacy – an upward trend with unpredictable effects. Dtsch Arztebl Int 2016; 113: 627-633
    CrossrefPubMedSearch in Google Scholar
  • 31 Wimmer BC, Cross AJ, Jokanovic N. et al Clinical Outcomes Associated with Medication Regimen Complexity in Older People: A Systematic Review. Journal of the American Geriatrics Society 2017; 65: 747-753
    CrossrefPubMedSearch in Google Scholar
  • 32 Steffel J, Verhamme P, Potpara TS. et al The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018; 39: 1330-1393
    CrossrefPubMedSearch in Google Scholar
  • 33 Masclee GM, Valkhoff VE, Coloma PM. et al Risk of upper gastrointestinal bleeding from different drug combinations. Gastroenterology 2014; 147: 784-792.e789 ; quiz e713–784.
    CrossrefPubMedSearch in Google Scholar
  • 34 Guo WQ, Chen XH, Tian XY. et al Differences In Gastrointestinal Safety Profiles Among Novel Oral Anticoagulants: Evidence From A Network Meta-Analysis. Clin Epidemiol 2019; 11: 911-921
    CrossrefPubMedSearch in Google Scholar
  • 35 Ray WA, Chung CP, Murray KT. et al Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy With Hospitalization for Upper Gastrointestinal Tract Bleeding. JAMA 2018; 320: 2221-2230
    Search in Google Scholar
  • 36 Xian Y, O'Brien EC, Liang L. et al Association of Preceding Antithrombotic Treatment With Acute Ischemic Stroke Severity and In-Hospital Outcomes Among Patients With Atrial Fibrillation. JAMA 2017; 317: 1057-1067
    CrossrefPubMedSearch in Google Scholar
  • 37 Patti G, Cavallari I, Hanon O. et al The safety and efficacy of non-vitamin K antagonist oral anticoagulants in atrial fibrillation in the elderly. Int J Cardiol 2018; 265: 118-124
    CrossrefPubMedSearch in Google Scholar
  • 38 Kato ET, Giugliano RP, Ruff CT. et al Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. J Am Heart Assoc 2016; 5: pii: e003432
    CrossrefPubMedSearch in Google Scholar
  • 39 Caldeira D, Nunes-Ferreira A, Rodrigues R. et al Non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: A systematic review with meta-analysis and trial sequential analysis. Arch Gerontol Geriatr 2019; 81: 209-214
    CrossrefPubMedSearch in Google Scholar
  • 40 Halvorsen S, Atar D, Yang H. et al Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J 2014; 35: 1864-1872
    CrossrefPubMedSearch in Google Scholar
  • 41 Donzé J, Clair C, Hug B. et al Risk of falls and major bleeds in patients on oral anticoagulation therapy. Am J Med 2012; 125: 773-778
    CrossrefPubMedSearch in Google Scholar
  • 42 Man-Son-Hing M, Nichol G, Lau A. et al Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Archives of internal medicine 1999; 159: 677-685
    CrossrefPubMedSearch in Google Scholar
  • 43 Rao MP, Vinereanu D, Wojdyla DM. et al Clinical Outcomes and History of Fall in Patients with Atrial Fibrillation Treated with Oral Anticoagulation: Insights From the ARISTOTLE Trial. Am J Med 2018; 131: 269-275 e262
    CrossrefPubMedSearch in Google Scholar
  • 44 Steffel J, Giugliano RP, Braunwald E. et al Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 Analysis. J Am Coll Cardiol 2016; 68: 1169-1178
    CrossrefPubMedSearch in Google Scholar
  • 45 Fanning L, Ryan-Atwood TE, Bell JS. et al Prevalence, Safety, and Effectiveness of Oral Anticoagulant Use in People with and without Dementia or Cognitive Impairment: A Systematic Review and Meta-Analysis. Journal of Alzheimer’s disease: JAD 2018; 65: 489-517
    CrossrefPubMedSearch in Google Scholar
  • 46 Bauersachs R, von Heymann C, Kemkes-Matthes B. et al Bluitungsrisiko und Nierenfunktion bestimmen das Vorgehen. Dtsch Arztebl 2019; 42: A1894-A1898
    PubMedSearch in Google Scholar
  • 47 Douketis JD, Spyropoulos AC, Duncan J. et al Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant. JAMA Intern Med 2019;
    CrossrefPubMedSearch in Google Scholar
  • 48 Colonna P, von Heymann C, Santamaria A. et al Routine clinical practice in the periprocedural management of edoxaban therapy is associated with low risk of bleeding and thromboembolic complications: The prospective, observational, and multinational EMIT-AF/VTE study. Clinical cardiology 2020; 43: 769-780
    CrossrefPubMedSearch in Google Scholar
  • 49 Kubitza D, Becka M, Voith B. et al Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clinical pharmacology and therapeutics 2005; 78: 412-421
    CrossrefPubMedSearch in Google Scholar
  • 50 Douketis JD, Spyropoulos AC, Kaatz S. et al Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. The New England journal of medicine 2015; 373: 823-833
    CrossrefPubMedSearch in Google Scholar
  • 51 Lin HJ, Wolf PA, Kelly-Hayes M. et al Stroke severity in atrial fibrillation. The Framingham Study. Stroke 1996; 27: 1760-1764
    CrossrefPubMedSearch in Google Scholar
  • 52 Marini C, De Santis F, Sacco S. et al Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke 2005; 36: 1115-1119
    CrossrefPubMedSearch in Google Scholar
  • 53 Seiffge DJ, Werring DJ, Paciaroni M. et al Timing of anticoagulation after recent ischaemic stroke in patients with atrial fibrillation. Lancet Neurol 2019; 18: 117-126
    CrossrefPubMedSearch in Google Scholar
  • 54 Kirchhof P, Benussi S, Kotecha D. et al 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37: 2893-2962
    CrossrefPubMedSearch in Google Scholar
  • 55 Paciaroni M, Agnelli G, Micheli S. et al Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials. Stroke 2007; 38: 423-430
    CrossrefPubMedSearch in Google Scholar
  • 56 Chen Z, Sandercock P, Pan H. et al Indications for Early Aspirin Use in Acute Ischemic Stroke. Stroke 2000; 31: 1240-1249
    CrossrefPubMedSearch in Google Scholar
  • 57 Rothwell PM, Algra A, Chen Z. et al Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials. The Lancet 2016; 388: 365-375
    CrossrefPubMedSearch in Google Scholar
  • 58 Sembill JA, Kuramatsu JB, Schwab S. et al Resumption of oral anticoagulation after spontaneous intracerebral hemorrhage. Neurological Research and Practice 2019; 1: 12
    CrossrefPubMedSearch in Google Scholar
  • 59 Korompoki E, Filippidis FT, Nielsen PB. et al Long-term antithrombotic treatment in intracranial hemorrhage survivors with atrial fibrillation. Neurology 2017; 89: 687-696
    CrossrefPubMedSearch in Google Scholar
  • 60 Ntaios G, Papavasileiou V, Diener HC. et al Nonvitamin-K-antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and previous stroke or transient ischemic attack: An updated systematic review and meta-analysis of randomized controlled trials. International Journal of Stroke 2017; 12: 589-596
    CrossrefPubMedSearch in Google Scholar
  • 61 Duchin K, Duggal A, Atiee GJ. et al An Open-Label Crossover Study of the Pharmacokinetics of the 60-mg Edoxaban Tablet Crushed and Administered Either by a Nasogastric Tube or in Apple Puree in Healthy Adults. Clinical pharmacokinetics 2018; 57: 221-228
    CrossrefPubMedSearch in Google Scholar
  • 62 Moore KT, Krook MA, Vaidyanathan S. et al Rivaroxaban crushed tablet suspension characteristics and relative bioavailability in healthy adults when administered orally or via nasogastric tube. Clinical pharmacology in drug development 2014; 3: 321-327
    CrossrefPubMedSearch in Google Scholar
  • 63 Kralev S, Schneider K, Lang S. et al Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography. PLoS One 2011; 6: e24964
    CrossrefPubMedSearch in Google Scholar
  • 64 Michniewicz E, Mlodawska E, Lopatowska P. et al Patients with atrial fibrillation and coronary artery disease – Double trouble. Advances in medical sciences 2018; 63: 30-35
    CrossrefPubMedSearch in Google Scholar
  • 65 Dewilde WJ, Oirbans T, Verheugt FW. et al Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013; 381: 1107-1115
    CrossrefPubMedSearch in Google Scholar
  • 66 Cannon CP, Bhatt DL, Oldgren J. et al Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. The New England journal of medicine 2017; 377: 1513-1524
    CrossrefPubMedSearch in Google Scholar
  • 67 Gibson CM, Mehran R, Bode C. et al Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. The New England journal of medicine 2016; 375: 2423-2434
    CrossrefPubMedSearch in Google Scholar
  • 68 Lopes RD, Heizer G, Aronson R. et al Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. The New England journal of medicine 2019; 380: 1509-1524
    CrossrefPubMedSearch in Google Scholar
  • 69 Vranckx P, Valgimigli M, Eckardt L. et al Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet 2019; 394: 1335-1343
    CrossrefPubMedSearch in Google Scholar
  • 70 Gargiulo G, Goette A, Tijssen J. et al Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. Eur Heart J 2019; 40: 3757-3767
    CrossrefPubMedSearch in Google Scholar
  • 71 Lopes RD, Leonardi S, Wojdyla DM. et al Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial. Circulation 2020; 141: 781-783
    CrossrefPubMedSearch in Google Scholar
  • 72 Goette A, Vranckx P. Atrial fibrillation patients undergoing percutaneous coronary intervention: dual or triple antithrombotic therapy with non-vitamin K antagonist oral anticoagulants. European Heart Journal Supplements 2020; 22: I22-I31
    CrossrefPubMedSearch in Google Scholar
  • 73 Limbruno U, Goette A, De Caterina R. Commentary: Temporarily omitting oral anticoagulants early after stenting for acute coronary syndromes patients with atrial fibrillation. Int J Cardiol 2020;
    CrossrefPubMedSearch in Google Scholar
  • 74 Ageno W, Beyer-Westendorf J, Rubboli A. Once- versus twice-daily direct oral anticoagulants in non-valvular atrial fibrillation. Expert opinion on pharmacotherapy 2017; 18: 1325-1332
    CrossrefPubMedSearch in Google Scholar
  • 75 Amara W, Antoniou S. Benefits of once-daily dosing with non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. European heart journal supplements: journal of the European Society of Cardiology 2016; 18: D1-D6
    CrossrefPubMedSearch in Google Scholar
  • 76 Hwang J, Han S, Bae HJ. et al NOAC Adherence of Patients with Atrial Fibrillation in the Real World: Dosing Frequency Matters?. Thromb Haemost 2020; 120: 306-313
    Thieme ConnectPubMedSearch in Google Scholar